The first 60 days: High-risk early HR-positive breast cancer
Most hormone-driven breast cancers are cured with surgery, radiotherapy and five to ten years of endocrine tablets. Women whose tumours are larger, higher grade or have reached the lymph nodes face a higher risk of relapse: two to three years of a CDK4/6 inhibitor added to endocrine therapy cuts recurrence, and genomic tests such as Oncotype DX and MammaPrint decide who also needs chemotherapy. Below, week by week, is what OnCo's record of High-risk early HR-positive breast cancer says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Deciding on chemotherapy, Adjuvant CDK4/6 inhibitor, Germline BRCA carriers, Local therapy.
- SurgeonNamed in the standard of care for: Local therapy.
- Medical oncologistNamed in the standard of care for: Deciding on chemotherapy, Endocrine therapy, Adjuvant CDK4/6 inhibitor, Germline BRCA carriers and 2 more.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Local therapy.
- Palliative and supportive care teamNamed in the standard of care for: Bone protection.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Abemaciclib for two years (monarchE, node-positive high-risk disease) or ribociclib for three years (NATALEE, stage II to III) alongside the aromatase inhibitor.
Genomic assay on node-negative and one to three node-positive tumours; chemotherapy for a high recurrence score, for premenopausal women with node-positive disease and a score up to 25, and for clinically high-risk tumours without a low genomic score.
Aromatase inhibitor for postmenopausal women; tamoxifen, or ovarian function suppression with an aromatase inhibitor for premenopausal women at higher risk (SOFT and TEXT); five years, extended to seven to ten in node-positive disease.
One year of adjuvant olaparib after chemotherapy for high-risk disease (OlympiA).
Breast-conserving surgery with hypofractionated whole-breast radiotherapy or mastectomy, sentinel node biopsy, and regional nodal irradiation when nodes are involved.
Zoledronic acid or denosumab during aromatase inhibitor therapy in postmenopausal women reduces fractures, and bisphosphonates also reduce bone recurrence.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Oestrogen and progesterone receptor percentage, HER2-negative status, Tumour grade and Ki-67, Nodal stage and tumour size, Oncotype DX recurrence score), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Luminal A-like, node-positive disease, Luminal B-like disease with high grade or high Ki-67, Node-positive disease with four or more nodes.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Deciding on chemotherapy
- For my situation (deciding on chemotherapy), which of the standard options do you recommend and why?Guideline options include: Genomic assay on node-negative and one to three node-positive tumours; chemotherapy for a high recurrence score, for premenopausal women with node-positive disease and a score up to 25, and for clinically high-risk tumours without a low genomic score.
- Am I a candidate for Oncotype DX, MammaPrint (70-gene signature), and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of TAILORx and RxPONDER (SWOG S1007) apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Endocrine therapy
- For my situation (endocrine therapy), which of the standard options do you recommend and why?Guideline options include: Aromatase inhibitor for postmenopausal women; tamoxifen, or ovarian function suppression with an aromatase inhibitor for premenopausal women at higher risk (SOFT and TEXT); five years, extended to seven to ten in node-positive disease.
- Am I a candidate for Letrozole (and other aromatase inhibitors), Exemestane, Tamoxifen or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of SOFT & TEXT apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Adjuvant CDK4/6 inhibitor
- For my situation (adjuvant cdk4/6 inhibitor), which of the standard options do you recommend and why?Guideline options include: Abemaciclib for two years (monarchE, node-positive high-risk disease) or ribociclib for three years (NATALEE, stage II to III) alongside the aromatase inhibitor.
- Am I a candidate for Abemaciclib, Ribociclib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of monarchE and NATALEE apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Germline BRCA carriers
- For my situation (germline brca carriers), which of the standard options do you recommend and why?Guideline options include: One year of adjuvant olaparib after chemotherapy for high-risk disease (OlympiA).
- Am I a candidate for Olaparib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of OlympiA apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Local therapy
- For my situation (local therapy), which of the standard options do you recommend and why?Guideline options include: Breast-conserving surgery with hypofractionated whole-breast radiotherapy or mastectomy, sentinel node biopsy, and regional nodal irradiation when nodes are involved.
Bone protection
- For my situation (bone protection), which of the standard options do you recommend and why?Guideline options include: Zoledronic acid or denosumab during aromatase inhibitor therapy in postmenopausal women reduces fractures, and bisphosphonates also reduce bone recurrence.
- Am I a candidate for Zoledronic acid, Denosumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of lidERA, CAMBRIA-1 & CAMBRIA-2, Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756), Giredestrant?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No test yet identifies the women whose relapse will come after ten years, when endocrine therapy has stopped”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Two to three years of a CDK4/6 inhibitor is costly and its overall survival benefit is not yet proven”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- CAMBRIA-1 & CAMBRIA-2Phase 3 · active · NCT05952557Adjuvant ER+/HER2- early breast cancer: camizestrant vs standard endocrine therapy, either after 2-5 years of prior ET (CAMBRIA-1) or upfront (CAMBRIA-2)
- Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)Phase 3 · active · NCT03725059A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- High-risk early HR-positive breast cancer: the full pageMost hormone-driven breast cancers are cured with surgery, radiotherapy and five to ten years of endocrine tablets. Women whose tumours are larger, higher grade or have reached the lymph nodes face a higher risk of relapse: two to three years of a CDK4/6 inhibitor added to endocrine therapy cuts recurrence, and genomic tests such as Oncotype DX and MammaPrint decide who also needs chemotherapy.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Lumpectomy (breast-conserving surgery): Removing only the tumour with a rim of normal breast, keeping the breast; almost always followed by radiotherapy.
- Mastectomy: Removing the whole breast, either for cancer or preventively in BRCA1/2 carriers, where bilateral risk-reducing mastectomy cuts breast cancer risk by 90% or more.
Every term links to the glossary.